[beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
A 55-year-old man was admitted to our hospital because of leukocytosis and microcytic anemia with hypochromia, target cells, and increased levels of hemoglobin A2 and hemoglobin F. The results of a gene analysis yielded a diagnosis of chronic myelogenous leukemia and beta-thalassemia minor. A gradual increase in hemoglobin was observed during hydroxyurea therapy, which was performed over a 12-week period. This increment appeared to be due to suppressed production of myeloid cells. It was been reported that hydroxyurea increases total hemoglobin due to increased hemoglobin F synthesis in patients with beta-thalassemia. However, hydroxyurea had no clear influence on hemoglobin concentration in this case.
Chiba
K
K
Third Department of Internal Medicine, Hokkaido University, School of Medicine.
Kurosawa
M
M
Kondo
T
T
Suzuki
S
S
Musashi
M
M
Asaka
M
M
Imamura
M
M
Hattori
Y
Y
Oba
Y
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005914:Globins / Q000235:genetics; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017086:beta-Thalassemia / Q000097:blood / Q000150:complications / Q000175:diagnosis*
D000970:Antineoplastic Agents; D006454:Hemoglobins; D005914:Globins; D006918:Hydroxyurea